Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $38 to $39.
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $38 to $39.